Interview with Federico Seghi Recli , Managing Director, Molteni
13.06.2010
Related Interviews
Italy / Gilead's Valentino Confalone on Eliminating Viral Hepatitis by 2030, HIV Pipeline Potential, & the Future of CAR-T
Gilead Sciences’ vice president and general manager for Italy, Valentino Confalone, outlines the company’s tumultuous pandemic journey in one of the first global epicentres; the role that Italy played in…
Italy / Gilead's Valentino Confalone on Eliminating Viral Hepatitis by 2030, HIV Pipeline Potential, & the Future of CAR-T
Can you begin by commenting on Gilead’s footprint in Italy, a country where the company has been present for just two decades? Even though it is relatively young, Gilead is…
Italy / Gilead's Valentino Confalone on Eliminating Viral Hepatitis by 2030, HIV Pipeline Potential, & the Future of CAR-T
Can you begin by commenting on Gilead’s footprint in Italy, a country where the company has been present for just two decades? Even though it is relatively young, Gilead is…
APAC / IFPMA's Thomas Cueni on the Value of Business Ethics for SMEs during COVID-19
Drawing on the findings of the Business Ethics for APEC SMEs Initiative, Thomas Cueni of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) outlines the benefits for small and…
Global / Astellas CMO Bernie Zeiher: Leaving No Stone Unturned in the Quest for Patient Value
Bernie Zeiher, chief medical officer (CMO) of Astellas explains why the ‘patient-defined value’ of medicines is crucial to developing therapies that truly address patients’ unmet medical needs. Zeiher outlines some…
Vaccine Nationalism / “Moral Obscenity, Public Health Catastrophe & Economic Folly”
Over two years since the first cases of COVID-19, the world is still coming to terms with the virus. While vaccines have been developed and rolled out in record time…
Latest Report
